Isis Reports Positive Interim Phase 2 Data on ISIS-APOCIII Rx

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced interim data from an ongoing Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with very high to severely high triglycerides. These data were presented today by Dr. Daniel Gaudet at a PACE session occurring concurrently with the European Society